Izotropic Corporation is focused on the commercialization of IzoView, a dedicated breast computed tomography (CT) imaging platform designed to enhance the detection and diagnosis of breast cancers. This innovative technology aims to provide a true 3D imaging experience, allowing for the acquisition of approximately 500 high-resolution images in just 10 seconds, with a radiation dose comparable to traditional mammography. The IzoView system is engineered to maintain patient comfort and dignity by eliminating painful breast compression, instead utilizing a unique imaging cup that allows for natural breast orientation. This approach not only improves the quality of images but also facilitates earlier detection of smaller tumors, potentially identifying lesions as small as 3-5 mm, which is significantly smaller than what is typically detected by standard mammography.

The development of IzoView is backed by extensive research and funding, including grants from the National Institutes of Health. The technology has undergone rigorous testing at UC Davis Medical Center, where it was initially developed. Izotropic's strategy includes a comprehensive clinical study to demonstrate the superior performance of IzoView compared to traditional diagnostic methods, with plans for market launch in the U.S. and subsequent expansion into other regions. The company is also exploring additional applications for the IzoView platform, aiming to provide solutions across various aspects of breast health care, including screening, treatment planning, and monitoring. This multifaceted approach positions Izotropic to significantly impact breast cancer diagnostics and improve patient outcomes.

Canada

Izotropic is a Medical Imaging company that specializes in making Breast CT an indispensable tool for improving breast cancer outcomes.

800-15355 24th Avenue, Surrey, British Columbia, CA, V4A 2H9

Izotropic Corp.

Company Details